NIKKEI 225
27,099.67 +107.46 (+0.40%) HANG SENG
18,013.24 +933.73 (+5.47%) CRUDE OIL
86.20 -0.32 (-0.37%) GOLD FUTURES
1,727.30 -3.20 (-0.18%) DOW
30,316.32 +825.43 (+2.80%) BTC-GBP
17,605.40 +385.43 (+2.24%)
Ocugen, Inc. (OCGN)
After hours:
| Previous close | 1.7800 |
| Open | 1.8400 |
| Bid | 0.0000 x 27000 |
| Ask | 0.0000 x 800 |
| Day's range | 1.8100 - 1.8750 |
| 52-week range | 1.6700 - 17.6500 |
| Volume | |
| Avg. volume | 5,286,264 |
| Market cap | 404.978M |
| Beta (5Y monthly) | 4.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why Ocugen Stock Topped the Market Today
Although it hasn't been the most popular coronavirus stock, Ocugen (NASDAQ: OCGN) clearly found some new fans on Thursday. In a one-two punch, Ocugen has appointed a new chief medical officer and chief scientific officer. The former is Robert Hopkins, a physician with over 20 years in both the public and private sectors of the healthcare industry.
- Motley Fool
Why Ocugen Stock Is Racing Higher Today
Shares of clinical-stage biotech Ocugen (NASDAQ: OCGN) are on fire today. Mizuho's analyst noted that Ocugen's shares are only currently being valued at the commercial potential of its COVID-19 vaccine known as Covaxin. Ocugen is co-commercializing the vaccine in North America with its developer Bharat Biotech of India.
- Motley Fool
Here's How This Beaten-Down Stock Could 10X by 2024
On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.
